EDIT 1997.

Methods	Randomised, parallel, interventional study
Participants	Participants 'at risk' for developing diabetes, fasting BG 5.5 to 7.7 mmol/L
Interventions	Metformin 500 mg three times daily plus placebo three times daily versus acarbose 50 mg three times daily plus placebo three times daily versus placebo three times daily plus placebo three times daily One of the intervention groups will not to be included in review (metformin 500 mg three times daily + acarbose 50 mg three times daily)
Outcomes	Incidence of T2DM, glycaemic variables
Publicaton details	Trial register record:ISRCTN96631607 The study is only published as abstracts
Notes	Conlcusion of the trial in published abstract": "No differences were seen in relative risk for diabetes by 6 years with acarbose (1.04, P = 0.81), Metformin (0.99, P = 0.94) or combination therapy (1.02, P = 0.91). In those with IGT at baseline, relative risk was reduced significantly with acarbose (0.66, P = 0.046) but not Metformin (1.09, P = 0.70) or combination therapy (0.72, P = 0.27)." The reviewers of Van de Laar 2006 have already asked for supplemental information.